Trends in health‐care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population‐based study

Trends in health‐care costs and utilization for inflammatory bowel disease from 2010 to 2014 in... IntroductionInflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, relapsing, and incurable disease with low mortality. As IBD predominantly affects young adults and carries a lifetime morbidity and low mortality, the disease places a considerable burden on public health and health‐care resources. Previous studies have demonstrated that the direct and indirect costs of IBD are considerably high. In two large population‐based studies from North America, the total IBD‐associated health‐care costs were estimated as $2.8 billion in Canada and $6.3 billion in the USA (US) per year. Additionally, the cost profile of IBD care has changed over time. Because highly effective biological therapies such as anti‐tumor necrosis factor (TNF) agents have been developed, the health‐care cost of IBD has shifted from hospitalization and surgery to anti‐TNF therapy in Europe.The incidence of IBD in Asia has risen steadily over the past few decades. A nationwide population‐based study of Korea showed that the mean annual incidence of UC was 4.6 per 100 000 and that of CD was 6.2 per 100 000 from 2006 to 2012. Cumulative epidemiologic data from Korea have showed that the incidence of IBD has increased about 10‐fold over two decades in Korea. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gastroenterology and Hepatology Wiley

Trends in health‐care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: A nationwide population‐based study

Loading next page...
 
/lp/wiley/trends-in-health-care-costs-and-utilization-for-inflammatory-bowel-QVrbETDCSO
Publisher
Wiley
Copyright
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
ISSN
0815-9319
eISSN
1440-1746
D.O.I.
10.1111/jgh.14027
Publisher site
See Article on Publisher Site

Abstract

IntroductionInflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, relapsing, and incurable disease with low mortality. As IBD predominantly affects young adults and carries a lifetime morbidity and low mortality, the disease places a considerable burden on public health and health‐care resources. Previous studies have demonstrated that the direct and indirect costs of IBD are considerably high. In two large population‐based studies from North America, the total IBD‐associated health‐care costs were estimated as $2.8 billion in Canada and $6.3 billion in the USA (US) per year. Additionally, the cost profile of IBD care has changed over time. Because highly effective biological therapies such as anti‐tumor necrosis factor (TNF) agents have been developed, the health‐care cost of IBD has shifted from hospitalization and surgery to anti‐TNF therapy in Europe.The incidence of IBD in Asia has risen steadily over the past few decades. A nationwide population‐based study of Korea showed that the mean annual incidence of UC was 4.6 per 100 000 and that of CD was 6.2 per 100 000 from 2006 to 2012. Cumulative epidemiologic data from Korea have showed that the incidence of IBD has increased about 10‐fold over two decades in Korea.

Journal

Journal of Gastroenterology and HepatologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off